RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized,...

Area of Science:

• Immunology
• Pharmacology
• Respiratory Medicine

Background:

• Interleukin-13 (IL-13) is a key cytokine in allergic inflammation and asthma pathogenesis.
• Targeting IL-13 signaling through its receptors (IL-13Rα1 and IL-13Rα2) is a therapeutic strategy for IL-13-mediated diseases.
• RPC4046 is a novel monoclonal antibody designed to block IL-13 binding to both IL-13Rα1 and IL-13Rα2.

Purpose of the Study:

• To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RPC4046 in a first-in-human study.
• To assess the efficacy of differential IL-13 receptor blockade in a murine asthma model.
• To investigate the impact of RPC4046 on IL-13 gene transcription in humans.

Main Methods:

• A murine asthma model was used to compare the efficacy of antibodies blocking IL-13Rα1 alone versus both IL-13Rα1 and IL-13Rα2.
• A randomized, double-blind, placebo-controlled, dose-escalation study was conducted in healthy adults and patients with mild to moderate asthma.
• Safety, tolerability, pharmacokinetic, and pharmacodynamic parameters, including gene transcription, were assessed.

Main Results:

• Blocking both IL-13 receptors in mice inhibited more asthma features and normalized IL-13 gene transcription more effectively than blocking IL-13Rα1 alone.
• RPC4046 demonstrated dose-dependent exposure in humans, with similar pharmacokinetics in healthy and asthmatic subjects.
• The antibody uniquely affected IL-13 gene transcription, and adverse events were generally mild to moderate, with no dose-related safety concerns or worsening of asthma symptoms.

Conclusions:

• RPC4046, an anti-IL-13 antibody blocking both IL-13 receptors, shows promise in fully blocking the asthma phenotype.
• The safety and unique pharmacodynamic profile support further investigation of RPC4046 for IL-13-related inflammatory diseases such as asthma and eosinophilic esophagitis.